• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 1, 2013

View Archived Issues

Single Asset Sends Ceptaris into Actelion's Arms

Ceptaris Therapeutics Inc. found a home for its single asset, Valchlor (mechlorethamine gel), with Actelion U.S. Holdings Co., a subsidiary of Swiss drugmaker Actelion Ltd. But there's a catch: The $250 million deal is contingent upon FDA approval of the product. Read More

DC Roundup: Sun To Start Shining on Physician Payments

From here on out, drugmakers can bet their bottom dollar the sun'll be shining on their financial dealings with doctors and teaching hospitals, but there are still a lot of cobwebs that need to be cleared away as the Physician Payment Sunshine Act goes into effect today. Read More

Cubist Acquisitions: Street Mutters About Optimer Price Cut

While Cubist Pharmaceuticals Inc.'s $1.6 billion double acquisition of Optimer Pharmaceuticals Inc. and Trius Therapeutics Inc. has gone down on the books as one of the biggest biotech events of the year, some analysts are crying foul at Optimer's surprisingly low selling price of $10.75 per share, or 20 percent below the stock's closing price of $13.29 on July 30, but it is barely more than 50 percent of the $20 per share offer Cubist made earlier this year. Read More

RNAi Resurgence Continues: Dicerna Closes $60M Series C

In one of the largest private financings for biotech this year, Dicerna Pharmaceuticals Inc. pulled in $60 million in a Series C round to move into the clinic with its lead RNAi-based candidates against genetically defined targets in disease areas such as oncology. Read More

Asmacure Seeks Better Fix for Asthma, COPD

When it comes to treating pulmonary disease, Asmacure Ltée is seeking to build a better mousetrap. Read More

Mouse Model of Hepatitis C Goes from Soup to Nuts

A new mouse model combines transgenes and tweaks to the innate immune system to make "a mouse model with heritable susceptibility to hepatitis C," Alexander Ploss told BioWorld Today. Read More

Other News To Note

• Elusys Therapeutics Inc., of Pine Brook, N.J., released data from three completed studies of ETI-204 (Anthim), an anthrax anti-toxin, administered by intramuscular injection (IM). Two of the studies assessed IM administration of ETI-204 following challenge with aerosolized B. anthracis spores (either before or after the development of symptoms of anthrax). Read More

Stock Movers

Read More

Clinic Roundup

• Delmar Pharmaceuticals Inc., of Vancouver, British Columbia, opened its third clinical trial site at the Brain Tumor Center at University of California, San Francisco. Delmar is conducting a Phase I/II dose-escalation study designed to assess the safety and activity of VAL-083 as a potential treatment for brain cancer patients suffering from glioblastoma multiforme (GBM) who have failed standard therapies and have no viable treatment options. Read More

Pharma: Other News To Note

• Life Technologies Corp., of Carlsbad, Calif., signed a long-term supply and exclusive licensing agreement with Novartis AG, of Basel, Switzerland, for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer. Read More

Pharma: Clinic Roundup

• Boehringer Ingelheim Pharmaceuticals GmbH, of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, jointly announced enrollment of the first patient into a cardiovascular (CV) and renal outcomes trial for the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (Tradjenta) tablets. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe